References
- Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians’ perspective. Rheumatology (Oxford) 2017;57:589.
- Chan CK, Holroyd CR, Mason A, Zarroug J, Edwards CJ. Are there dangers in biologic dose reduction strategies? Autoimmun Rev 2016;15:742–6.
- Lau CS, Gibofsky A, Damjanov N, Lula S, Marshall L, Jones H, et al. Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review. Rheumatol Int 2017;37:1789–98.
- Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77.
- Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2015;68:1–26.
- Marks JL, Holroyd CR, Dimitrov BD, Armstrong RD, Calogeras A, Cooper C, et al. Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy? Arthritis Care Res (Hoboken) 2015;67:746–53.
- Garcia I, Portugal C, Chu LH, Kawatkar AA. Response rates of three modes of survey administration and survey preferences of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013;66:364–70.